Latest News in the pharma Industry

Research & Development

Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

17 Sep 2015

Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, Januvia (sitagliptin), at reducing patients’ A1C levels from baseline, with similar A1C reductions achieved in both groups.

Read more 
Using proteomics to understand how genetic mutations rewire cancer cells

Using proteomics to understand how genetic mutations rewire cancer cells

17 Sep 2015

Scientific publications highlight studies using data from Thermo Scientific Orbitrap mass spectrometry and next-generation sequencing to discover how cancer attacks the protein networks controlling human cells

Read more 
BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

16 Sep 2015

This is the fourth Breakthrough Therapy Designation granted for Opdivo by the FDA

Read more 
Opsonix launches with $8 million Series A to develop pathogen-extracting therapy for sepsis and other blood-borne infectious diseases

Opsonix launches with $8 million Series A to develop pathogen-extracting therapy for sepsis and other blood-borne infectious diseases

8 Oct 2015

The company’s sepsis therapy has the potential to be used not only in combination with existing antibiotics, but also to treat patients when conventional therapeutic options are not available.

Read more 
Navitor Pharmaceuticals’ scientific founder makes landmark discovery of the molecular sensor for the amino acid leucine

Navitor Pharmaceuticals’ scientific founder makes landmark discovery of the molecular sensor for the amino acid leucine

8 Oct 2015

Finding the long sought-after mediator of mTORC1 activation by leucine opens up opportunities for creating new medicines for metabolic, musculoskeletal, autoimmune and other age-related diseases.

Read more 
FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia

FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia

26 Aug 2015

Read more 
Allergan and Gedeon Richter to present data from Cariprazine trials at ECNP annual meeting

Allergan and Gedeon Richter to present data from Cariprazine trials at ECNP annual meeting

26 Aug 2015

Read more 
Oncodrone receives €2.5 million Eurostars grant

Oncodrone receives €2.5 million Eurostars grant

26 Aug 2015

Read more 
BMS and Pfizer to present new data on Eliquis (apixaban) at the ESC Congress 2015

BMS and Pfizer to present new data on Eliquis (apixaban) at the ESC Congress 2015

25 Aug 2015

Read more 
NIH study shows no benefit of omega-3 or other nutritional supplements for cognitive decline

NIH study shows no benefit of omega-3 or other nutritional supplements for cognitive decline

25 Aug 2015

Read more 
Takeda announces EMA acceptance of ixazomib's MAA for patients with relapsed/refractory multiple myeloma

Takeda announces EMA acceptance of ixazomib's MAA for patients with relapsed/refractory multiple myeloma

24 Aug 2015

Read more 
Alkermes provides update on FDA review of Aristada for the treatment of schizophrenia

Alkermes provides update on FDA review of Aristada for the treatment of schizophrenia

24 Aug 2015

Read more